ストックスクリーナーアプリを入手
152.90
5.23%
7.6025
Insmed Inc (INSM) 最新ニュース
Insmed (NASDAQ:INSM) Stock Price Up 6.3% Following Analyst Upgrade - MarketBeat
Stifel reiterates Insmed stock rating on rival trial success By Investing.com - Investing.com Canada
Insmed stock gains on UTHR trial read-through, Morgan Stanley upgrade - Investing.com Canada
Leerink reiterates Insmed stock rating on TPIP franchise potential - investing.com
Morgan Stanley upgrades Insmed stock rating on Brinsupri launch data - Investing.com
Morgan Stanley upgrades Insmed stock rating on Brinsupri launch data By Investing.com - Investing.com Canada
Equities Analysts Issue Forecasts for Insmed Q2 Earnings - MarketBeat
Insmed (INSM) poised for 2026 upside with potential $1.3B Arikayce sales boost, Roth/MKM initiates buy - MSN
SG Americas Securities LLC Buys 49,356 Shares of Insmed, Inc. $INSM - MarketBeat
Positive Phase 3b study update sees Insmed stock drop 1.56% - Traders Union
Nordea Investment Management AB Makes New Investment in Insmed, Inc. $INSM - MarketBeat
Vanguard disaggregates holdings; Insmed (NASDAQ: INSM) shows 0 shares - Stock Titan
Assenagon Asset Management S.A. Sells 22,419 Shares of Insmed, Inc. $INSM - MarketBeat
INSM Stock: HC Wainwright & Co. Raises Price Target to $245 | IN - GuruFocus
Insmed (NASDAQ:INSM) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
H.C. Wainwright raises Insmed stock price target on ARIKAYCE data - Investing.com
INSM Stock Price, Quote & Chart | INSMED INC (NASDAQ:INSM) - ChartMill
Insmed shares rise on positive results from ARIKAYCE Phase 3b study - MSN
Insmed jumps 6.6% as attention returns to upcoming ENCORE readout for ARIKAYCE - Quiver Quantitative
Insmed CEO reveals Japan patient population exceeds US market for lung disease - AOL.com
Insmed (NASDAQ:INSM) Price Target Raised to $206.00 at Mizuho - MarketBeat
INSM Stock: Mizuho Raises Price Target Amid Stable Outlook | INS - GuruFocus
Insmed (NASDAQ:INSM) Price Target Upgrades Drive Nasdaq Index Focus - Kalkine Media
Wells Fargo Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $177 - Moomoo
INSM: Leerink Partners Raises Price Target, Maintains Outperform Rating | INSM Stock News - GuruFocus
INSM: Wells Fargo Raises Price Target to $177, Reaffirms Overwei - GuruFocus
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ionis Pharmaceuticals (IONS), GE Healthcare Technologies Inc (GEHC) and Insmed (INSM) - The Globe and Mail
B of A Securities Maintains Buy Rating for INSM, Raises Price Ta - GuruFocus
Insmed Stock Hits Day Low of $135.73 Amid Price Pressure - Markets Mojo
Apogee Therapeutics, Insmed, Sunoco - TradingView
Insmed (NASDAQ:INSM) Price Target Raised to $215.00 at Leerink Partners - MarketBeat
A Quick Look at Today's Ratings for Insmed(INSM.US), With a Forecast Between $143.69 to $243 - Moomoo
INSM shares rise following Arikayce's successful outcome in label expansion trial - Bitget
Stifel Nicolaus Issues Positive Forecast for Insmed (NASDAQ:INSM) Stock Price - MarketBeat
INSM: Stifel Raises Price Target, Continues Buy Rating | INSM St - GuruFocus
Mizuho raises Insmed stock price target on positive trial data By Investing.com - Investing.com Canada
Mizuho raises Insmed stock price target on positive trial data - investing.com
Mizuho Securities Maintains Insmed(INSM.US) With Buy Rating, Raises Target Price to $206 - Moomoo
INSM Stock Gains After Arikayce Hits Goal in Label Expansion Study - TradingView
Bank of America Forecasts Strong Price Appreciation for Insmed (NASDAQ:INSM) Stock - MarketBeat
Insmed eyes Arikayce label expansion on Phase IIIb lung disease success - Yahoo Finance
Stifel raises Insmed stock price target on positive trial data - Investing.com
Mizuho Lifts Price Target on Insmed to $206 From $204, Keeps Outperform Rating - marketscreener.com
Stocks Flashing Renewed Technical Strength: Insmed - Investor's Business Daily
Insmed reports positive Phase 3b trial results for MAC lung disease drug - Investing.com Australia
Insmed’s New Lung Disease Study Data A Win For Company, Says Analyst - Stocktwits
A Look At Insmed (INSM) Valuation After Positive ENCORE Phase 3b ARIKAYCE Data - Yahoo Finance
Analyst weighs patent cliff risks against Insmed’s (INSM) growth story - MSN
Insmed CEO on its Arikayce drug after shares surge on trial results - MSN
Insmed Shares Climb on Positive Results for Arikayce - marketscreener.com
Market movers: Palantir Technologies, Insmed, Synopsys… - Proactive financial news
Insmed Announces Positive Phase 3b ENCORE Results for ARIKAYCE in MAC Lung Disease, Plans FDA Supplemental NDA Filing in 2026 - Minichart
BofA raises Insmed stock price target on positive trial data By Investing.com - Investing.com Canada
Insmed (INSM) Achieves Milestone with Positive Phase 3 ENCORE Tr - GuruFocus
Insmed Lung Infection Therapy Data Impresses, Analyst Sees Approval Path - benzinga.com
Insmed ENCORE Phase 3 Trial Hits Primary Endpoint; ARIKAYCE Drives Strong MAC Culture Conversion Gains - MarketBeat
Insmed (INSM): ENCORE Phase 3 Success Expands MAC Lung Disease Opportunity and Underscores Arikayce Upside - TipRanks
Insmed rises on late-stage trial results for Arikayce for lung infection - Seeking Alpha
Jefferies raises Insmed stock price target on positive trial data By Investing.com - Investing.com Canada
Insmed’s Arikayce data tees up sNDA filing in MAC lung disease - The Pharma Letter
Pulmonary Arterial Hypertension Market: Expanding Revenue Landscape to 2034 – DelveInsight | Merck, Janssen Pharma, Aerovate Therapeutics, Novartis, Insmed Inc, Chugai Pharma, Keros Therapeutics - Barchart.com
Jefferies raises Insmed stock price target on positive trial data - Investing.com
Insmed shares rise as Arikayce trial data point to larger market opportunity - Investing.com Canada
Wolfe Research reiterates Insmed stock rating on Brinsupri momentum - Investing.com
Insmed (NASDAQ:INSM) Shares Gap UpWhat's Next? - MarketBeat
Wolfe Research reiterates Insmed stock rating on Brinsupri momentum By Investing.com - Investing.com Canada
0.77%
0.61%
大文字化:
|
ボリューム (24 時間):